NL-OMON47241已完成4 期
A phase 4, monocenter, randomized, double-blind, comparator-controlled, parallel-group, mechanistic intervention trial to assess the effect of 12-week treatment with the sodium-glucose linked transporters (SGLT)-2 inhibitor dapagliflozin versus the sulfonylurea (SU) derivative gliclazide on renal physiology and biomarkers in metformin-treated patients with type 2 diabetes mellitus (T2DM) - RED: Renoprotective Effects of Dapagliflozin in Type 2 Diabetes
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Inclusion criteria
- •* Caucasian*
- •* Both genders (females must be post-menopausal; no menses < 1 year; in case of doubt, Follicle-Stimulating Hormone (FSH) will be determined with cut-off defined as > 31 U/L)
- •* Age: 35 - 75 years
- •* BMI: >25 kg/m2
- •* HbA1c: 6.5 * 9.0% Diabetes Control and Complications Trial (DCCT) or 48 - 86 mmol/mol International Federation of Clinical Chemistry (IFCC)
- •* Treatment with a stable dose of oral antihyperglycemic agents for at least 3 months prior to inclusion
- •* Metformin monotherapy
- •* Combination of metformin and low dose SU derivative**
- •* Hypertension should be controlled, i.e. *140/90 mmHg, and treated with an ACE-I or ARB (unless prevented by side effect) for at least 3 months.
- •* Albuminuria should be treated with a RAAS-interfering agent (ACE-I or ARB) for at least 3 months.
- •* Written informed consent;* In order to increase homogeneity
- •** In order to accelerate inclusion, patients using combined metformin/SU derivative will be considered. In these patients, a 12 week wash-out period of the SU derivative will be observed, only when combined use has led to a HbA1c <8% at screening. Subsequently, patients will be eligible to enter the study, now using metformin monotherapy, provided that HbA1c still meets inclusion criteria.
排除标准
- •Exclusion criteria
- •* History of unstable or rapidly progressing renal disease
- •* Estimated GFR<60 mL/min/1.73m2 (determined by the Modification of Diet in Renal Disease (MDRD) study equation)
- •* Current/chronic use of the following medication: TZD, SU derivative, GLP-1RA, DPP-4I, SGLT-2 inhibitors, glucocorticoids, immune suppressants, antimicrobial agents, chemotherapeutics, antipsychotics, tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). Subjects on diuretics will only be excluded when these drugs cannot be stopped for the duration of the study.
- •* Volume depleted patients. Patients at risk for volume depletion due to co-existing conditions or concomitant medications, such as loop diuretics should have careful monitoring of their volume status.
- •* Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) will not be allowed, unless used as incidental medication (1-2 tablets) for non-chronic indications (i.e. sports injury, head-ache or back ache). However, no such drugs can be taken within a time-frame of 2 weeks prior to renal-testing
- •* History of diabetic ketoacidosis (DKA) requiring medical intervention (eg, emergency room visit and/or hospitalization) within 1 month prior to the Screening visit.
- •* Current urinary tract infection and active nephritis
- •* Recent (<6 months) history of cardiovascular disease, including:
- •o Acute coronary syndrome
- •o Chronic heart failure (New York Heart Association grade II-IV)
- •o Stroke or transient ischemic neurologic disorder
- •* Complaints compatible with neurogenic bladder and/or incomplete bladder emptying (as determined by ultrasonic bladder scan)
- •* Severe hepatic insufficiency and/or significant abnormal liver function defined as aspartate aminotransferase (AST) >3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) >3x ULN
- •* (Unstable) thyroid disease; defined as fT4 outside of laboratory reference values or change in treatment within 3 months prior to screening visit
- •* History of or actual malignancy (except basal cell carcinoma)
- •* History of or actual severe mental disease
- •* Substance abuse (alcohol: defined as >4 units/day)
- •* Allergy to any of the agents used in the study
- •* Individuals who are investigator site personnel, directly affiliated with the study, or are immediate (spouse, parent, child, or sibling, whether biological or legally adopted) family of investigator site personnel directly affiliated with the study
- •* Inability to understand the study protocol or give informed consent
研究者
相似试验
已完成
4 期
A phase 4, monocenter, randomized, double-blind, comparator-controlled, parallel-group, mechanistic intervention trial to assess the effect of 8-week treatment with the dipeptidyl peptidase-4 inhibitor (DPP-4i) linagliptin versus the sulfonylurea (SU) derivative glimepiride on renal physiology and biomarkers in metformin-treated patients with type 2 diabetes mellitus (T2DM)1001842410029149Type 2 Diabetes MellitusNL-OMON41714Vrije Universiteit Medisch Centrum48
进行中（未招募）
1 期
The renal actions of combined empagliflozin and linagliptin in type 2 diabetesType 2 Diabetes MellitusEUCTR2017-001547-12-NLVU University Medical Center66
已完成
4 期
A phase 4, monocenter, randomized, double-blind, comparator-controlled, 3-armed parallel mechanistic intervention trial to assess the effect of 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, followed by 8-week empagliflozin and linagliptin (DPP-4 inhibitor) combination therapy versus 8-week linagliptin monotherapy, followed by 8-week linagliptin and empagliflozin combination therapy versus 8-week gliclazide (Sulfonylurea derivate), followed by 8-week gliclazide intensification therapy on rType 2 Diabetes MellitusNL-OMON48622Vrije Universiteit Medisch Centrum66
进行中（未招募）
1 期
The renal effects of the new glucose lowering drug dapagliflozin with another glucose lowering drug gliclazide in type 2 diabetes mellitus patientsType 2 Diabetes MellitusEUCTR2015-003818-24-NLVU University Medical Center44
已完成
4 期
A phase 4, monocenter, randomized, double-blind, placebo-controlled, 4-armed cross-over mechanistic intervention study to assess the renal hemodynamic effect of mono- and combination therapy with empagliflozin (SGLT-2 inhibitor) and losartan (RAS inhibitor) in metformin and/or SU-treated patients with type 2 diabetes mellitus10029149adult-onset diabetes1001842410003216Type 2 Diabetes MellitusNL-OMON49031Vrije Universiteit Medisch Centrum24